Greater Glasgow and Clyde Medicines
Key to symbols The medicine should be initiated by, or on the advice of a specialist, but is suitable for continuation by a GP The medicine should only be used and prescribed by a specialist Indicates the preferred choice within a class or group of medicines
The medicine should be initiated by, or on the advice of a specialist, but is suitable for continuation by a GP
The medicine should only be used and prescribed by a specialist
Indicates the preferred choice within a class or group of medicines
4. Central nervous system

4.5. Drugs used in the treatment of obesity

4.5.1. Anti-obesity drugs acting on the gastro-intestinal tract

Preferred List
ORLISTAT

Restrictions:

Restricted to use for patients with BMI >30 with relevant co-morbidities and BMI >35 without co-morbidities. Other conditions for prescribing should be in accordance with the Glasgow and Clyde Weight Management Service protocol. It should be prescribed only on the advice of the Glasgow and Clyde Weight Management Service.

BNF Link

4.5.2. Centrally acting appetite suppressants

Total Formulary
Specialist and GP
LIRAGLUTIDE (Saxenda) (injection)

Restrictions:

Restricted to initiation only on the advice of the Glasgow and Clyde Specialist Weight Management Service as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of BMI ≥35kg/m² (obesity class II and above) with:

  • Non-diabetic hyperglycaemia (prediabetes) at high risk of type 2 diabetes which is defined as having either:
    • Fasting plasma glucose level of 5.5 to 6.9mmol/L or
    • HbA1c of 6.0 to 6.4% (42 to 47mmol/mol), and
  • High risk of cardiovascular disease (CVD):
    • Total cholesterol >5mmol/L, or
    • High-density lipoprotein (HDL) <1.0mmol/L for men and <1.3mmol/L for women, or
    • Systolic blood pressure (SBP) >140mmHg

 

Prescribing Notes:

**Current nationwide supply problem. No new patients should be initiated on Saxenda until supply problem has resolved and a pathway has been agreed and implemented**

 

 

 

BNF Link